Glucagon in type 2 diabetes: Friend or foe?
NAFLD
cotadutide
diabetic kidney disease
dual agonists
glucagon
type 2 diabetes
Journal
Diabetes/metabolism research and reviews
ISSN: 1520-7560
Titre abrégé: Diabetes Metab Res Rev
Pays: England
ID NLM: 100883450
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
02
12
2022
received:
23
08
2022
accepted:
30
12
2022
pubmed:
14
1
2023
medline:
7
3
2023
entrez:
13
1
2023
Statut:
ppublish
Résumé
Hyperglucagonemia is one of the 'ominous' eight factors underlying the pathogenesis of type 2 diabetes (T2D). Glucagon is a peptide hormone involved in maintaining glucose homoeostasis by increasing hepatic glucose output to counterbalance insulin action. Long neglected, the introduction of dual and triple agonists exploiting glucagon signalling pathways has rekindled the interest in this hormone beyond its classic effect on glycaemia. Glucagon can promote weight loss by regulating food intake, energy expenditure, and brown and white adipose tissue functions through mechanisms still to be fully elucidated, thus its role in T2D pathogenesis should be further investigated. Moreover, the role of glucagon in the development of T2D micro- and macro-vascular complications is elusive. Mounting evidence suggests its beneficial effect in non-alcoholic fatty liver disease, while few studies postulated its favourable role in peripheral neuropathy and retinopathy. Contrarily, glucagon receptor agonism might induce renal changes resembling diabetic nephropathy, and data concerning glucagon actions on the cardiovascular system are conflicting. This review aims to summarise the available findings on the role of glucagon in the pathogenesis of T2D and its complications. Further experimental and clinical data are warranted to better understand the implications of glucagon signalling modulation with new antidiabetic drugs.
Substances chimiques
Glucagon
9007-92-5
Hypoglycemic Agents
0
Glucose
IY9XDZ35W2
Glucagon-Like Peptide-1 Receptor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3609Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Haedersdal S, Lund A, Knop FK, Vilsbøll T. The role of glucagon in the pathophysiology and treatment of type 2 diabetes. Mayo Clin Proc. 2018;93(2):217-239. https://doi.org/10.1016/j.mayocp.2017.12.003
Unger RH, Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet. 1975;1(7897):14-16. https://doi.org/10.1016/s0140-6736(75)92375-2
Marrano N, Biondi G, Cignarelli A, et al. Functional loss of pancreatic islets in type 2 diabetes: how can we halt it? Metabolism. 2020;110:154304. https://doi.org/10.1016/j.metabol.2020.154304
Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, Caicedo A. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci USA. 2006;103(7):2334-2339. https://doi.org/10.1073/pnas.0510790103
Gilon P. The role of α-cells in islet function and glucose homeostasis in health and type 2 diabetes. J Mol Biol. 2020;432(5):1367-1394. https://doi.org/10.1016/j.jmb.2020.01.004
Cooperberg BA, Cryer PE. Insulin reciprocally regulates glucagon secretion in humans. Diabetes. 2010;59(11):2936-2940. https://doi.org/10.2337/db10-0728
Huising MO. Paracrine regulation of insulin secretion. Diabetologia. 2020;63(10):2057-2063. https://doi.org/10.1007/s00125-020-05213-5
Bertuzzi F, Berra C, Socci C, et al. Glucagon improves insulin secretion from pig islets in vitro. J Endocrinol. 1995;147(1):87-93. https://doi.org/10.1677/joe.0.1470087
Pipeleers D, In't Veld PI, Maes E, Van De Winkel M. Glucose-induced insulin release depends on functional cooperation between islet cells. Proc Natl Acad Sci USA. 1982;79(23):7322-7325. https://doi.org/10.1073/pnas.79.23.7322
Huypens P, Ling Z, Pipeleers D, Schuit F. Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia. 2000;43(8):1012-1019. https://doi.org/10.1007/s001250051484
Trimble ER, Halban PA, Wollheim CB, Renold AE. Functional differences between rat islets of ventral and dorsal pancreatic origin. J Clin Invest. 1982;69(2):405-413. https://doi.org/10.1172/jci110464
Reissaus CA, Piston DW. Reestablishment of glucose inhibition of glucagon secretion in small pseudoislets. Diabetes. 2017;66(4):960-969. https://doi.org/10.2337/db16-1291
Capozzi ME, Svendsen B, Encisco SE, et al. β cell tone is defined by proglucagon peptides through cAMP signaling. JCI Insight. 2019;4(5). https://doi.org/10.1172/jci.insight.126742
Zhu L, Dattaroy D, Pham J, et al. Intra-islet glucagon signaling is critical for maintaining glucose homeostasis. JCI Insight. 2019;5(10). https://doi.org/10.1172/jci.insight.127994
Thorel F, Damond N, Chera S, et al. Normal glucagon signaling and β-cell function after near-total α-cell ablation in adult mice. Diabetes. 2011;60(11):2872-2882. https://doi.org/10.2337/db11-0876
DiGruccio MR, Mawla AM, Donaldson CJ, et al. Comprehensive alpha, beta and delta cell transcriptomes reveal that ghrelin selectively activates delta cells and promotes somatostatin release from pancreatic islets. Mol Metab. 2016;5(7):449-458. https://doi.org/10.1016/j.molmet.2016.04.007
Noguchi GM, Huising MO. Integrating the inputs that shape pancreatic islet hormone release. Nat Metab. 2019;1(12):1189-1201. https://doi.org/10.1038/s42255-019-0148-2
Moede T, Leibiger IB, Berggren PO. Alpha cell regulation of beta cell function. Diabetologia. 2020;63(10):2064-2075. https://doi.org/10.1007/s00125-020-05196-3
Capozzi ME, Wait JB, Koech J, et al. Glucagon lowers glycemia when β-cells are active. JCI Insight. 2019;5(16). https://doi.org/10.1172/jci.insight.129954
Svendsen B, Larsen O, Gabe MBN, et al. Insulin secretion depends on intra-islet glucagon signaling. Cell Rep. 2018;25(5):1127-1134.e2. https://doi.org/10.1016/j.celrep.2018.10.018
Chambers AP, Sorrell JE, Haller A, et al. The role of pancreatic preproglucagon in glucose homeostasis in mice. Cell Metab. 2017;25(4):927-934.e3. https://doi.org/10.1016/j.cmet.2017.02.008
Gelling RW, Vuguin PM, Du XQ, et al. Pancreatic beta-cell overexpression of the glucagon receptor gene results in enhanced beta-cell function and mass. Am J Physiol Endocrinol Metab. 2009;297(3):E695-E707. https://doi.org/10.1152/ajpendo.00082.2009
Maharaj A, Zhu L, Huang F, et al. Ectopic expression of glucagon receptor in skeletal muscles improves glucose homeostasis in a mouse model of diabetes. Diabetologia. 2012;55(5):1458-1468. https://doi.org/10.1007/s00125-012-2464-x
Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2000;85(11):4053-4059. https://doi.org/10.1210/jcem.85.11.6993
Ali S, Drucker DJ. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab. 2009;296(3):E415-E421. https://doi.org/10.1152/ajpendo.90887.2008
Ahrén B. Glucagon - early breakthroughs and recent discoveries. Peptides. 2015;67:74-81. https://doi.org/10.1016/j.peptides.2015.03.011
Menge BA, Grüber L, Jørgensen SM, et al. Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes. Diabetes. 2011;60(8):2160-2168. https://doi.org/10.2337/db11-0251
Henquin JC, Ibrahim MM, Rahier J. Insulin, glucagon and somatostatin stores in the pancreas of subjects with type-2 diabetes and their lean and obese non-diabetic controls. Sci Rep. 2017;7(1):11015. https://doi.org/10.1038/s41598-017-10296-z
Lee Y, Berglund ED, Yu X, et al. Hyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells. Proc Natl Acad Sci USA. 2014;111(36):13217-13222. https://doi.org/10.1073/pnas.1409638111
Merino B, Casanueva-Álvarez E, Quesada I, et al. Insulin-degrading enzyme ablation in mouse pancreatic alpha cells triggers cell proliferation, hyperplasia and glucagon secretion dysregulation. Diabetologia. 2022;65(8):1375-1389. https://doi.org/10.1007/s00125-022-05729-y
Jamison RA, Stark R, Dong J, et al. Hyperglucagonemia precedes a decline in insulin secretion and causes hyperglycemia in chronically glucose-infused rats. Am J Physiol Endocrinol Metab. 2011;301(6):E1174-E1183. https://doi.org/10.1152/ajpendo.00175.2011
Solomon TP, Knudsen SH, Karstoft K, Winding K, Holst JJ, Pedersen BK. Examining the effects of hyperglycemia on pancreatic endocrine function in humans: evidence for in vivo glucotoxicity. J Clin Endocrinol Metab. 2012;97(12):4682-4691. https://doi.org/10.1210/jc.2012-2097
Liu W, Kin T, Ho S, et al. Abnormal regulation of glucagon secretion by human islet alpha cells in the absence of beta cells. EBioMedicine. 2019;50:306-316. https://doi.org/10.1016/j.ebiom.2019.11.018
Liu Z, Kim W, Chen Z, et al. Insulin and glucagon regulate pancreatic α-cell proliferation. PLoS One. 2011;6(1):e16096. https://doi.org/10.1371/journal.pone.0016096
Ellingsgaard H, Ehses JA, Hammar EB, et al. Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci USA. 2008;105(35):13163-13168. https://doi.org/10.1073/pnas.0801059105
Sørensen H, Winzell MS, Brand CL, et al. Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function. Diabetes. 2006;55(12):3463-3469. https://doi.org/10.2337/db06-0307
Vuguin PM, Kedees MH, Cui L, et al. Ablation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturation. Endocrinology. 2006;147(9):3995-4006. https://doi.org/10.1210/en.2005-1410
Wang Q, Liang X, Wang S. Intra-islet glucagon secretion and action in the regulation of glucose homeostasis. Front Physiol. 2012;3:485. https://doi.org/10.3389/fphys.2012.00485
Unger RH, Orci L. Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci USA. 2010;107(37):16009-16012. https://doi.org/10.1073/pnas.1006639107
Wewer Albrechtsen NJ, Kuhre RE, Pedersen J, Knop FK, Holst JJ. The biology of glucagon and the consequences of hyperglucagonemia. Biomark Med. 2016;10(11):1141-1151. https://doi.org/10.2217/bmm-2016-0090
Ciudad C, Camici M, Ahmad Z, Wang Y, DePaoli-Roach AA, Roach PJ. Control of glycogen synthase phosphorylation in isolated rat hepatocytes by epinephrine, vasopressin and glucagon. Eur J Biochem. 1984;142(3):511-520. https://doi.org/10.1111/j.1432-1033.1984.tb08315.x
Tavares CDJ, Aigner S, Sharabi K, et al. Transcriptome-wide analysis of PGC-1α-binding RNAs identifies genes linked to glucagon metabolic action. Proc Natl Acad Sci USA. 2020;117(36):22204-22213. https://doi.org/10.1073/pnas.2000643117
Lu M, Wan M, Leavens KF, et al. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat Med. 2012;18(3):388-395. https://doi.org/10.1038/nm.2686
Rena G, Guo S, Cichy SC, Unterman TG, Cohen P. Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem. 1999;274(24):17179-17183. https://doi.org/10.1074/jbc.274.24.17179
Wu Y, Pan Q, Yan H, et al. Novel mechanism of foxo1 phosphorylation in glucagon signaling in control of glucose homeostasis. Diabetes. 2018;67(11):2167-2182. https://doi.org/10.2337/db18-0674
Perry RJ. Regulation of hepatic lipid and glucose metabolism by INSP3R1. Diabetes. 2022;71(9):1834-1841. https://doi.org/10.2337/dbi22-0003
Perry RJ, Zhang D, Guerra MT, et al. Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis. Nature. 2020;579(7798):279-283. https://doi.org/10.1038/s41586-020-2074-6
Pégorier JP, Garcia-Garcia MV, Prip-Buus C, Duée PH, Kohl C, Girard J. Induction of ketogenesis and fatty acid oxidation by glucagon and cyclic AMP in cultured hepatocytes from rabbit fetuses. Evidence for a decreased sensitivity of carnitine palmitoyltransferase I to malonyl-CoA inhibition after glucagon or cyclic AMP treatment. Biochem J. 1989;264(1):93-100. https://doi.org/10.1042/bj2640093
Preedy VR, Garlick PJ. The effect of glucagon administration on protein synthesis in skeletal muscles, heart and liver in vivo. Biochem J. 1985;228(3):575-581. https://doi.org/10.1042/bj2280575
Hartl WH, Miyoshi H, Jahoor F, Klein S, Elahi D, Wolfe RR. Bradykinin attenuates glucagon-induced leucine oxidation in humans. Am J Physiol. 1990;259(2 Pt 1):E239-E245. https://doi.org/10.1152/ajpendo.1990.259.2.E239
Pacy PJ, Cheng KN, Ford GC, Halliday D. Influence of glucagon on protein and leucine metabolism: a study in fasting man with induced insulin resistance. Br J Surg. 1990;77(7):791-794. https://doi.org/10.1002/bjs.1800770723
Adeva-Andany MM, Fernández-Fernández C, López-Pereiro Y, Castro-Calvo I, Carneiro-Freire N. The effects of glucagon and the target of rapamycin (TOR) on skeletal muscle protein synthesis and age-dependent sarcopenia in humans. Clin Nutr ESPEN. 2021;44:15-25. https://doi.org/10.1016/j.clnesp.2021.06.025
Boden G, Tappy L, Jadali F, Hoeldtke RD, Rezvani I, Owen OE. Role of glucagon in disposal of an amino acid load. Am J Physiol. 1990;259(2 Pt 1):E225-E232. https://doi.org/10.1152/ajpendo.1990.259.2.E225
Thiessen SE, Gunst J, Van den Berghe G. Role of glucagon in protein catabolism. Curr Opin Crit Care. 2018;24(4):228-234. https://doi.org/10.1097/MCC.0000000000000509
Chen SS, Zhang Y, Santomango TS, Williams PE, Lacy DB, McGuinness OP. Glucagon chronically impairs hepatic and muscle glucose disposal. Am J Physiol Endocrinol Metab. 2007;292(3):E928-E935. https://doi.org/10.1152/ajpendo.00063.2006
Yasuda S, Takechi M, Ono M, et al. The effect of glucagon on FDG uptake in skeletal muscle. Tokai J Exp Clin Med. 2012;37(1):11-13.
Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tschöp MH. The metabolic actions of glucagon revisited. Nat Rev Endocrinol. 2010;6(12):689-697. https://doi.org/10.1038/nrendo.2010.187
Rudman D, Del Rio AE. Responsiveness to lipolytic hormones, and inactivation of adrenocorticotropin, by adipose tissue slices and free fat cells from different mammalian species. Endocrinology. 1969;85(2):209-213. https://doi.org/10.1210/endo-85-2-209
Kuroshima A, Yahata T. Thermogenic responses of brown adipocytes to noradrenaline and glucagon in heat-acclimated and cold-acclimated rats. Jpn J Physiol. 1979;29(6):683-690. https://doi.org/10.2170/jjphysiol.29.683
Seitz HJ, Krone W, Wilke H, et al. Rapid rise in plasma glucagon induced by acute cold exposure in man and rat. Pflugers Arch. 1981;389(2):115-120. https://doi.org/10.1007/BF00582100
Habara Y, Kuroshima A. Changes in glucagon and insulin contents of brown adipose tissue after temperature acclimation in rats. Jpn J Physiol. 1983;33(4):661-665. https://doi.org/10.2170/jjphysiol.33.661
Kinoshita K, Ozaki N, Takagi Y, Murata Y, Oshida Y, Hayashi Y. Glucagon is essential for adaptive thermogenesis in brown adipose tissue. Endocrinology. 2014;155(9):3484-3492. https://doi.org/10.1210/en.2014-1175
Beaudry JL, Kaur KD, Varin EM, et al. The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice. Mol Metab. 2019;22:37-48. https://doi.org/10.1016/j.molmet.2019.01.011
Billington CJ, Bartness TJ, Briggs J, Levine AS, Morley JE. Glucagon stimulation of brown adipose tissue growth and thermogenesis. Am J Physiol. 1987;252(1 Pt 2):R160-R165. https://doi.org/10.1152/ajpregu.1987.252.1.R160
Habegger KM, Stemmer K, Cheng C, et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes. 2013;62(5):1453-1463. https://doi.org/10.2337/db12-1116
Whytock KL, Carnero EA, Vega RB, et al. Prolonged glucagon infusion does not affect energy expenditure in individuals with overweight/obesity: a randomized trial. Obesity. 2021;29(6):1003-1013. https://doi.org/10.1002/oby.23141
Townsend LK, Medak KD, Knuth CM, Peppler WT, Charron MJ, Wright DC. Loss of glucagon signaling alters white adipose tissue browning. FASEB J. 2019;33(4):4824-4835. https://doi.org/10.1096/fj.201802048RR
Cantini G, Trabucco M, Di Franco A, Mannucci E, Luconi M. Glucagon modulates proliferation and differentiation of human adipose precursors. J Mol Endocrinol. 2019;63(4):249-260. https://doi.org/10.1530/JME-19-0095
Stern JH, Smith GI, Chen S, Unger RH, Klein S, Scherer PE. Obesity dysregulates fasting-induced changes in glucagon secretion. J Endocrinol. 2019;243(2):149-160. https://doi.org/10.1530/JOE-19-0201
Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1987;64(1):106-110. https://doi.org/10.1210/jcem-64-1-106
Peng IC, Chen Z, Sun W, et al. Glucagon regulates ACC activity in adipocytes through the CAMKKβ/AMPK pathway. Am J Physiol Endocrinol Metab. 2012;302(12):E1560-E1568. https://doi.org/10.1152/ajpendo.00504.2011
Cegla J, Troke RC, Jones B, et al. Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes. 2014;63(11):3711-3720. https://doi.org/10.2337/db14-0242
Salem V, Izzi-Engbeaya C, Coello C, et al. Glucagon increases energy expenditure independently of brown adipose tissue activation in humans. Diabetes Obes Metab. 2016;18(1):72-81. https://doi.org/10.1111/dom.12585
Campos RV, Lee YC, Drucker DJ. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology. 1994;134(5):2156-2164. https://doi.org/10.1210/endo.134.5.8156917
Del Prato S, Gallwitz B, Holst JJ, Meier JJ. The incretin/glucagon system as a target for pharmacotherapy of obesity. Obes Rev. 2022;23(2):e13372. https://doi.org/10.1111/obr.13372
Tan TM, Field BC, McCullough KA, et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes. 2013;62(4):1131-1138. https://doi.org/10.2337/db12-0797
Le Sauter J, Noh U, Geary N. Hepatic portal infusion of glucagon antibodies increases spontaneous meal size in rats. Am J Physiol. 1991;261(1 Pt 2):R162-R165. https://doi.org/10.1152/ajpregu.1991.261.1.R162
Mighiu PI, Yue JT, Filippi BM, et al. Hypothalamic glucagon signaling inhibits hepatic glucose production. Nat Med. 2013;19(6):766-772. https://doi.org/10.1038/nm.3115
Geary N, Le Sauter J, Noh U. Glucagon acts in the liver to control spontaneous meal size in rats. Am J Physiol. 1993;264(1 Pt 2):R116-R122. https://doi.org/10.1152/ajpregu.1993.264.1.R116
Weatherford SC, Ritter S. Lesion of vagal afferent terminals impairs glucagon-induced suppression of food intake. Physiol Behav. 1988;43(5):645-650. https://doi.org/10.1016/0031-9384(88)90220-x
Quiñones M, Al-Massadi O, Gallego R, et al. Hypothalamic CaMKKβ mediates glucagon anorectic effect and its diet-induced resistance. Mol Metab. 2015;4(12):961-970. https://doi.org/10.1016/j.molmet.2015.09.014
Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Oikawa S. Effects of insulin, leptin, and glucagon on ghrelin secretion from isolated perfused rat stomach. Regul Pept. 2004;119(1-2):77-81. https://doi.org/10.1016/j.regpep.2004.01.012
Katayama T, Shimamoto S, Oda H, Nakahara K, Kangawa K, Murakami N. Glucagon receptor expression and glucagon stimulation of ghrelin secretion in rat stomach. Biochem Biophys Res Commun. 2007;357(4):865-870. https://doi.org/10.1016/j.bbrc.2007.04.001
Mochiki E, Suzuki H, Takenoshita S, et al. Mechanism of inhibitory effect of glucagon on gastrointestinal motility and cause of side effects of glucagon. J Gastroenterol. 1998;33(6):835-841. https://doi.org/10.1007/s005350050184
Soule S, Pemberton C, Hunt P, Cole D, Raudsepp S, Inder W. Prandial regulation of ghrelin secretion in humans: does glucagon contribute to the preprandial increase in circulating ghrelin? Clin Endocrinol. 2005;63(4):412-417. https://doi.org/10.1111/j.1365-2265.2005.02357.x
Patel GK, Whalen GE, Soergel KH, Wu WC, Meade RC. Glucagon effects on the human small intestine. Dig Dis Sci. 1979;24(7):501-508. https://doi.org/10.1007/BF01489316
Ponce J, Garrigues V, Pertejo V, et al. Effect of intravenous glucagon and glucagon-(1-21)-peptide on motor activity of sphincter of Oddi in humans. Dig Dis Sci. 1989;34(1):61-64. https://doi.org/10.1007/BF01536155
Pascaud X, Ferre JP, Genton M, Roger A, Ruckebusch M, Bueno L. Intestinal motility responses to insulin and glucagon in streptozotocin diabetic rats. Can J Physiol Pharmacol. 1982;60(7):960-967. https://doi.org/10.1139/y82-135
Gutzeit A, Binkert CA, Koh DM, et al. Evaluation of the anti-peristaltic effect of glucagon and hyoscine on the small bowel: comparison of intravenous and intramuscular drug administration. Eur Radiol. 2012;22(6):1186-1194. https://doi.org/10.1007/s00330-011-2366-1
Charron MJ, Vuguin PM. Lack of glucagon receptor signaling and its implications beyond glucose homeostasis. J Endocrinol. 2015;224(3):R123-R130. https://doi.org/10.1530/JOE-14-0614
Godoy-Matos AF. The role of glucagon on type 2 diabetes at a glance. Diabetol Metab Syndr. 2014;6(1):91. https://doi.org/10.1186/1758-5996-6-91
Farah AE. Glucagon and the circulation. Pharmacol Rev. 1983;35(3):181-217.
Gonzalez-Muñoz C, Nieto-Cerón S, Cabezas-Herrera J, Hernández-Cascales J. Glucagon increases contractility in ventricle but not in atrium of the rat heart. Eur J Pharmacol. 2008;587(1-3):243-247. https://doi.org/10.1016/j.ejphar.2008.04.001
Ceriello A, Genovese S, Mannucci E, Gronda E. Glucagon and heart in type 2 diabetes: new perspectives. Cardiovasc Diabetol. 2016;15(1):123. https://doi.org/10.1186/s12933-016-0440-3
Harney JA, Rodgers RL. Insulin-like stimulation of cardiac fuel metabolism by physiological levels of glucagon: involvement of PI3K but not cAMP. Am J Physiol Endocrinol Metab. 2008;295(1):E155-E161. https://doi.org/10.1152/ajpendo.90228.2008
Müller TD, Finan B, Clemmensen C, DiMarchi RD, Tschöp MH. The new biology and pharmacology of glucagon. Physiol Rev. 2017;97(2):721-766. https://doi.org/10.1152/physrev.00025.2016
Linhart JW, Barold SS, Cohen LS, Hildner FJ, Samet P. Cardiovascular effects of glucagon in man. Am J Cardiol. 1968;22(5):706-710. https://doi.org/10.1016/0002-9149(68)90209-9
Hernández-Cascales J. Does glucagon have a positive inotropic effect in the human heart? Cardiovasc Diabetol. 2018;17(1):148. https://doi.org/10.1186/s12933-018-0791-z
Ali S, Ussher JR, Baggio LL, et al. Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction. Mol Metab. 2015;4(2):132-143. https://doi.org/10.1016/j.molmet.2014.11.005
Gao C, Ren SV, Yu J, et al. Glucagon receptor antagonism ameliorates progression of heart failure. JACC Basic Transl Sci. 2019;4(2):161-172. https://doi.org/10.1016/j.jacbts.2018.11.001
Sharma AX, Quittner-Strom EB, Lee Y, et al. Glucagon receptor antagonism improves glucose metabolism and cardiac function by promoting AMP-mediated protein kinase in diabetic mice. Cell Rep. 2018;22(7):1760-1773. https://doi.org/10.1016/j.celrep.2018.01.065
Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev. 2007;28(3):253-283. https://doi.org/10.1210/er.2006-0026
Takao T, Matsuyama Y, Yanagisawa H, Kikuchi M, Kawazu S. Association between HbA1c variability and mortality in patients with type 2 diabetes. J Diabetes Complicat. 2014;28(4):494-499. https://doi.org/10.1016/j.jdiacomp.2014.02.006
Cryer PE. Minireview: glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology. 2012;153(3):1039-1048. https://doi.org/10.1210/en.2011-1499
Janah L, Kjeldsen S, Galsgaard KD, et al. Glucagon receptor signaling and glucagon resistance. Int J Mol Sci. 2019;20(13):3314. https://doi.org/10.3390/ijms20133314
Huang HX, Shen LL, Huang HY, et al. Associations of plasma glucagon levels with estimated glomerular filtration rate, albuminuria and diabetic kidney disease in patients with type 2 diabetes mellitus. Diabetes Metab J. 2021;45(6):868-879. https://doi.org/10.4093/dmj.2020.0149
Mohiuddin MS, Himeno T, Yamada Y, et al. Glucagon prevents cytotoxicity induced by methylglyoxal in a rat neuronal cell line model. Biomolecules. 2021;11(2):287. https://doi.org/10.3390/biom11020287
Bankir L, Bouby N, Speth RC, Velho G, Crambert G. Glucagon revisited: coordinated actions on the liver and kidney. Diabetes Res Clin Pract. 2018;146:119-129. https://doi.org/10.1016/j.diabres.2018.10.004
Bankir L, Roussel R, Bouby N. Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea. Am J Physiol Ren Physiol. 2015;309(1):F2-F23. https://doi.org/10.1152/ajprenal.00614.2014
Li XC, Liao TD, Zhuo JL. Long-term hyperglucagonaemia induces early metabolic and renal phenotypes of type 2 diabetes in mice. Clin Sci. 2008;114(9):591-601. https://doi.org/10.1042/CS20070257
Li XC, Zhuo JL. Targeting glucagon receptor signalling in treating metabolic syndrome and renal injury in type 2 diabetes: theory versus promise. Clin Sci. 2007;113(4):183-193. https://doi.org/10.1042/CS20070040
Liu JJ, Liu S, Gurung RL, et al. Relationship between fasting plasma glucagon level and renal function - a cross-sectional study in individuals with type 2 diabetes. J Endocr Soc. 2019;3(1):273-283. https://doi.org/10.1210/js.2018-00321
Wang X, Yang J, Chang B, et al. Glucagon secretion is increased in patients with type 2 diabetic nephropathy. J Diabetes Complicat. 2016;30(3):488-493. https://doi.org/10.1016/j.jdiacomp.2015.12.020
Takeda Y, Fujita Y, Bessho R, et al. Increment of plasma glucose by exogenous glucagon is associated with present and future renal function in type 2 diabetes: a retrospective study from glucagon stimulation test. BMC Endocr Disord. 2019;19(1):99. https://doi.org/10.1186/s12902-019-0428-6
Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793-801. https://doi.org/10.1016/j.jhep.2019.06.021
Khandelwal R, Dassanayake AS, Conjeevaram HS, Singh SP. Non-alcoholic fatty liver disease in diabetes: when to refer to the hepatologist? World J Diabetes. 2021;12(9):1479-1493. https://doi.org/10.4239/wjd.v12.i9.1479
Galsgaard KD. The vicious circle of hepatic glucagon resistance in non-alcoholic fatty liver disease. J Clin Med. 2020;9(12):4049. https://doi.org/10.3390/jcm9124049
Wewer Albrechtsen NJ, Pedersen J, Galsgaard KD, et al. The liver-α-cell axis and type 2 diabetes. Endocr Rev. 2019;40(5):1353-1366. https://doi.org/10.1210/er.2018-00251
McGlone ER, Ansell TB, Dunsterville C, et al. Hepatocyte cholesterol content modulates glucagon receptor signalling. Mol Metab. 2022;63:101530. https://doi.org/10.1016/j.molmet.2022.101530
Winther-Sørensen M, Galsgaard KD, Santos A, et al. Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis. Mol Metab. 2020;42:101080. https://doi.org/10.1016/j.molmet.2020.101080
Suppli MP, Bagger JI, Lund A, et al. Glucagon resistance at the level of amino acid turnover in obese subjects with hepatic steatosis. Diabetes. 2020;69(6):1090-1099. https://doi.org/10.2337/db19-0715
Zhang L, Yao W, Xia J, Wang T, Huang F. Glucagon-induced acetylation of energy-sensing factors in control of hepatic metabolism. Int J Mol Sci. 2019;16(8):20. https://doi.org/10.3390/ijms20081885
Junker AE, Gluud L, Holst JJ, Knop FK, Vilsbøll T. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. J Intern Med. 2016;279(5):485-493. https://doi.org/10.1111/joim.12462
Wang Y, Lin Z, Wan H, et al. Glucagon is associated with NAFLD inflammatory progression in type 2 diabetes, not with NAFLD fibrotic progression. Eur J Gastroenterol Hepatol. 2021;33(1S Suppl 1):e818-e823. https://doi.org/10.1097/MEG.0000000000002269
Anoop S, Misra A, Bhatt SP, Gulati S, Mahajan H, Prabakaran G. High plasma glucagon levels correlate with waist-to-hip ratio, suprailiac skinfold thickness, and deep subcutaneous abdominal and intraperitoneal adipose tissue depots in nonobese Asian Indian males with type 2 diabetes in North India. J Diabetes Res. 2017;2017:2376016. https://doi.org/10.1155/2017/2376016
Moh Moh MA, Jung CH, Lee B, et al. Association of glucagon-to-insulin ratio and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2019;16(2):186-195. https://doi.org/10.1177/1479164118810691
Pedersen JS, Rygg MO, Kristiansen VB, et al. Nonalcoholic fatty liver disease impairs the liver-alpha cell axis independent of hepatic inflammation and fibrosis. Hepatol Commun. 2020;4(11):1610-1623. https://doi.org/10.1002/hep4.1562
Gar C, Haschka SJ, Kern-Matschilles S, et al. The liver-alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels. Diabetologia. 2021;64(3):512-520. https://doi.org/10.1007/s00125-020-05334-x
Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? Clin Diabetes Endocrinol. 2020;6(1):9. https://doi.org/10.1186/s40842-020-00097-1
Nason SR, Kim T, Antipenko JP, et al. Glucagon-receptor signaling reverses hepatic steatosis independent of leptin receptor expression. Endocrinology. 2020;161(1). https://doi.org/10.1210/endocr/bqz013
Patil M, Deshmukh NJ, Patel M, Sangle GV. Glucagon-based therapy: past, present and future. Peptides. 2020;127:170296. https://doi.org/10.1016/j.peptides.2020.170296
Chai S, Zhang R, Zhang Y, et al. Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: a systemic review and meta-analysis. Front Endocrinol. 2022;13:994944. https://doi.org/10.3389/fendo.2022.994944
Spiliotis II, Chalk R, Gough S, Rorsman P. Reducing hyperglucagonaemia in type 2 diabetes using low-dose glibenclamide: results of the LEGEND-A pilot study. Diabetes Obes Metab. 2022;24(8):1671-1675. https://doi.org/10.1111/dom.14740
Pettus JH, D'Alessio D, Frias JP, et al. Efficacy and safety of the glucagon receptor antagonist RVT-1502 in type 2 diabetes uncontrolled on metformin monotherapy: a 12-week dose-ranging study. Diabetes Care. 2020;43(1):161-168. https://doi.org/10.2337/dc19-1328
Haedersdal S, Lund A, Maagensen H, et al. The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetes. Eur J Endocrinol. 2022;186(2):207-221. https://doi.org/10.1530/EJE-21-0865
Haedersdal S, Lund A, Nielsen-Hannerup E, et al. The glucagon receptor antagonist LY2409021 does not affect gastrointestinal-mediated glucose disposal or the incretin effect in individuals with and without type 2 diabetes. Eur J Endocrinol. 2022;187(4):507-518. https://doi.org/10.1530/EJE-22-0291
Capozzi ME, DiMarchi RD, Tschöp MH, Finan B, Campbell JE. Targeting the incretin/glucagon system with triagonists to treat diabetes. Endocr Rev. 2018;39(5):719-738. https://doi.org/10.1210/er.2018-00117
Irwin DM, Prentice KJ. Incretin hormones and the expanding families of glucagon-like sequences and their receptors. Diabetes Obes Metab. 2011;13(Suppl 1):69-81. https://doi.org/10.1111/j.1463-1326.2011.01444.x
Ambery PD, Klammt S, Posch MG, et al. MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, phase 1 study. Br J Clin Pharmacol. 2018;84(10):2325-2335. https://doi.org/10.1111/bcp.13688
Parker VER, Robertson D, Wang T, et al. Efficacy, safety, and mechanistic insights of cotadutide, a dual receptor glucagon-like peptide-1 and glucagon agonist. J Clin Endocrinol Metab. 2020;105(3):803-820. https://doi.org/10.1210/clinem/dgz047
Ambery P, Parker VE, Stumvoll M, et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018;391(10140):2607-2618. https://doi.org/10.1016/s0140-6736(18)30726-8
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. https://doi.org/10.1093/eurheartj/ehab484
Nahra R, Wang T, Gadde KM, et al. Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study. Diabetes Care. 2021;44(6):1433-1442. https://doi.org/10.2337/dc20-2151
Parker VER, Hoang T, Schlichthaar H, et al. Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2022;24(7):1360-1369. https://doi.org/10.1111/dom.14712
Schiavon M, Visentin R, Göbel B, et al. Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide. Diabetes Obes Metab. 2021;23(8):1795-1805. https://doi.org/10.1111/dom.14394
Kannt A, Madsen AN, Kammermeier C, et al. Incretin combination therapy for the treatment of non-alcoholic steatohepatitis. Diabetes Obes Metab. 2020;22(8):1328-1338. https://doi.org/10.1111/dom.14035
Jain M, Tsai L-F, Robertson D, et al. MEDI0382, a GLP/glucagon receptor dual agonist, significantly reduces hepatic fat content in subjects with type 2 diabetes mellitus. Diabetes. 2018;67(1):78-OR. https://doi.org/10.2337/db18-78-or
Choi JH, Lee JS, Kim JK, et al. Multi-target engagement effect of a novel long-acting glucagon/GIP/GLP-1 triple agonist (HM15211) in animal model of NASH. Diabetes. 2021;70(Supplement_1):655-P.
Boland ML, Laker RC, Mather K, et al. Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis. Nat Metab. 2020;2(5):413-431. https://doi.org/10.1038/s42255-020-0209-6
Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27-36. https://doi.org/10.1038/nm.3761
Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-795. https://doi.org/10.2337/db09-9028
Arafat MA, Otto B, Rochlitz H, et al. Glucagon inhibits ghrelin secretion in humans. Eur J Endocrinol. 2005;153(3):397-402. https://doi.org/10.1530/eje.1.01981